Diabetes Patients Withdrawn from Avandia Are Most Likely Switched to the New First-in-class Agents, Januvia or Byetta, According to Tns Healthcare
NEW YORK, November 29, 2007— New research
from TNS Healthcare’s DiabetesDynamics USA™ shows that
between July and September 2007 just over half of all patients
taken off Avandia because of reported links to cardiac risk…
Bavarian Nordic A/S Reports Positive Data from First EUA Enabling Study with Imvamune Smallpox Vaccine
KVISTGAARD, Denmark, Nov. 29, 2007-Bavarian Nordic reports the
successful completion of a large, placebo-controlled Phase II trial
in 745 healthy subjects who received either one or two doses of
Imvamune third-generation smallpox vaccine. The…
Regeneron Initiates Major Global Collaboration with Sanofi-aventis to Develop and Commercialize Fully-Human Therapeutic Antibodies
TARRYTOWN, N.Y.–(BUSINESS WIRE)–Nov 29, 2007 - Regeneron
Pharmaceuticals, Inc. (Nasdaq: REGN) and sanofi-aventis (Euronext:
SAN and NYSE: SNY) announced today that they have entered into a
global, strategic collaboration agreement to discover,…
New LJS Study Finds Broad Consumer Acceptance of Behind-The-Counter Drugs
CHICAGO, November 29, 2007 /PRNewswire/ — A study by Leo J.
Shapiro & Associates (LJS) reveals that two-thirds of Americans
believe the U.S. Food and Drug Administration (FDA) should make
certain drugs obtainable without a prescription, but…
Drug Monitoring Reduces Seizures in Pregnant Women with Epilepsy
“It’s really a benefit for both mothers and babies.”
A popular epilepsy drug taken by pregnant women with epilepsy because of its mild risk of birth defects has been linked to increased seizure activity in up to 75 percent of pregnancies. via Newswise
ChemGenex Announces Shareholder Approval to Demerge Verva Pharmaceuticals
MELBOURNE, Australia & MENLO PARK, Calif.–(BUSINESS WIRE)–Nov
29, 2007 - ChemGenex Pharmaceuticals Limited (ASX:CXS) and
(NASDAQ:CXSP) today announced that at the company’s Annual General
Meeting yesterday it received shareholder approval for…
OPKO Health Completes Acquisition of Ophthalmic Technologies, Inc.
MIAMI, November 29, 2007 /PRNewswire-FirstCall/ — OPKO Health
Inc. today announced that it has completed the previously announced
acquisition of Ophthalmic Technologies, Inc. (OTI), a privately
owned Canadian company providing innovative ocular…
Exelixis to Receive Milestone Payment From Bristol-Myers Squibb for Achievement of Liver X Receptor Agonist Development Milestone
SOUTH SAN FRANCISCO, Calif., November 29, 2007
/PRNewswire-FirstCall/ — Exelixis, Inc. today announced that its
right to receive from Bristol-Myers Squibb a milestone payment of
$5 million was triggered as a result of the acceptance of…
Cell Protein Might Help Treat ALS
“This is another piece of the puzzle of what causes ALS and how best to treat it. It’s possible that one day a treatment based on this finding could be part of a ‘cocktail’ for attacking the disease from different fronts”
Studies in mice point to a possible treatment for amyotrophic lateral sclerosis , also known as Lou Gehrig’s disease. via WNEP-TV Moosic
Men give up too fast if impotence pill fails: study
“These data confirm that men are still reluctant to seek help for their erectile dysfunction and highlight the importance of first-time success on improving aspects of well-being”
LONDON (Reuters) - A third of men with erectile dysfunction could not perform after taking their first tablet of an impotence drug and gave up sex entirely, according to a study presented at the European Society of Sexual Medicine on Tuesday.
The findings show the importance of the first-time pill for erectile dysfunction patients who could potentially see better results by switching tablets or increasing the dose, Dr. David Edwards, a general practitioner in Oxfordshire in England, and colleagues said. Read more
« go back — keep looking »